Loading
Edesa Biotech, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Brooks Michael J, was filed 11 Mar 2026.
Edesa Biotech, Inc.: what insiders have been doing
Every trade that managers of Edesa Biotech, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. 19 insiders have disclosed 47 filings since 23 October 2025.
The record shows 11 purchases on the open market worth €228k, made by 4 insiders, against 2 sales worth €121k by 1 insider. Netting one side against the other leaves €107k of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a sale of €109k from Lemieux, Stephen, disclosed on 23 March 2026. On the buying side, the filings list 2 senior executives and 2 chief executives among the declarants.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 11 March 2026, 227 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade.
With 47 filings in twelve months, the company is more active than the median of 24 filings across the 3,169 companies we follow on the same exchange. Our records for Edesa Biotech, Inc. go back to 2019, with 69 purchases and 15 sales on the open market in total.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
216
Thresholds
n/a
Buy Volume
€1M
69 ops. · all time
Sell Volume
€2M
15 ops. · all time
Who traded when
BuySalePardeep Nijhawan9 buys
Lemieux, Stephen2 sales
Michael Brooks1 buy
Michael J. Brooks1 buy
Since the insiders bought
- -18.3%Entry US$6.38 · Close at T+90 US$5.21
- -25.4%Entry US$6.62 · Close at T+90 US$4.94
- +43.1%Entry US$24.22 · Close at T+365 US$34.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended September 2025 · cache
US$2.76
Analyst consensus
3 analysts1.00/5
US$9.00Target US$16.33(+492%)US$21.00
Income statement
EBITDA-US$7M
Net income-US$7.2M0.0% margin
Valuation
P/Book67.3x
Beta1.22
Balance sheet & cash
Market capUS$37.3M
Free Cash Flow-US$7.3M
Profitability & ownership
ROE-122.9%
ROA-66.4%
% insiders13.6%
% institutions37.4%
Last declaration on 6 October 2026
Declarations216 total
6,893 shares0Common SharesSEC:0001171843-26-006472:0
5,714 shares0Common SharesSEC:0001171843-26-005844:0
5,324 shares0Common SharesSEC:0001171843-26-005208:0
153,530 shares@ CA$5.210.93% mcap100.0% of flowCommon SharesTSXSEDI:4736614
153,550 sharesCommon SharesSEC:0001171843-26-004151:0
64,609 sharesRestricted Share UnitsTSXSEDI:4726433
19,000 sharesRestricted Share UnitsTSXSEDI:4726284
19,000 sharesRestricted Share UnitsTSXSEDI:4726278
19,000 sharesRestricted Share UnitsTSXSEDI:4726250
64,609 sharesRestricted Share UnitsTSXSEDI:4726240
96,913 sharesRestricted Share UnitsTSXSEDI:4726235
19,000 sharesRestricted Share UnitsTSXSEDI:4726229
19,000 sharesRestricted Share UnitsTSXSEDI:4726226
19,000 sharesRestricted Share UnitsTSXSEDI:4726223
1,671 shares0Common SharesSEC:0001171843-26-003842:0
64,609 shares0Common SharesSEC:0001171843-26-003801:0
19,000 shares0Common SharesSEC:0001171843-26-003803:0
19,000 shares0Common SharesSEC:0000921895-26-001502:0
96,913 shares0Common SharesSEC:0001171843-26-003797:0
19,000 shares0Common SharesSEC:0001171843-26-003799:0
19,000 shares0Common SharesSEC:0001171843-26-003800:0
64,609 shares0Common SharesSEC:0001171843-26-003802:0
19,000 shares0Common SharesSEC:0001171843-26-003804:0
19,000 shares0Common SharesSEC:0001171843-26-003805:0
1,159 shares0Common SharesSEC:0001171843-26-002942:0
25 of 216 declarations
About Edesa Biotech, Inc.
Edesa Biotech, Inc. is a company focused on developing treatments for inflammatory diseases and dermatological disorders. It is listed on NASDAQ under the ticker EDSA.
